玻璃體注射康柏西普治療152例糖尿病黃斑水腫的療效及安全性

李慧俐+孫雅楠+劉丹+韓新剛

摘 要 目的：觀察康柏西普針玻璃體注射治療糖尿病黃斑水腫的療效及安全性。方法：選擇糖尿病黃斑水腫患者152例152眼，根據(jù)治療方法不同分成觀察組和對(duì)照組各76例76眼。觀察組給予康柏西普針玻璃體注射治療，對(duì)照組給予曲安奈德玻璃體注射治療。觀察比較兩組治療前后視力、黃斑中心視網(wǎng)膜厚度和眼壓的變化及術(shù)后并發(fā)癥情況。結(jié)果：兩組治療后4周、8周、12周各時(shí)間點(diǎn)視力均明顯高于治療前，且不同時(shí)間點(diǎn)黃斑中心視網(wǎng)膜厚度均較治療前減少（P<0.05）；觀察組治療后不同時(shí)間點(diǎn)眼壓值無(wú)顯著變化，對(duì)照組治療后不同時(shí)間點(diǎn)眼壓值與治療前相比均顯著升高（P<0.05）；治療后觀察組眼壓升高的發(fā)生率低于對(duì)照組（P<0.05）。結(jié)論：康柏西普針玻璃體注射治療糖尿病黃斑水腫可明顯提高視力，減輕黃斑水腫程度，療效與曲安奈德玻璃體注射治療相當(dāng)，且安全性更好。

關(guān)鍵詞 康柏西普針 玻璃體注射 糖尿病黃斑水腫 視力 眼壓

中圖分類(lèi)號(hào)：R988.1； R774.5 文獻(xiàn)標(biāo)識(shí)碼：A 文章編號(hào)：1006-1533（2017）19-0015-03

Efficacy and safety of intravitreal injection of Compaq in the treatment of 152 patients with diabetic macular edema

LI Huili*， SUN Yannan， LIU Dan， HAN Xingang（Department of Ophthalmology， General Hospital of Pingmei Group in Pingdingshan City of Henan Province， Pingdingshan 467000， China）

ABSTRACT Objective： To observe the efficacy and safety of intravitreal injection of Compaq in the treatment of diabetic macular edema. Methods： One hundred and fifty-two eyes of 152 patients with diabetic macular edema were divided into an observation group and a control group with 76 eyes each based on different treatment methods. The patients in the observation group were treated with intravitreal injection of compaq while with intravitreal injection of triamcinolone acetonide in the control group. The changes of visual acuity， macular central retinal thickness， intraocular pressure and the complications were observed and compared between the two groups before and after treatment. Results： The visual acuity at each time point of postoperative 4， 8 and 12 weeks was significantly higher and the macular retinal thickness was thinner after treatment than before （P<0.05）. Intraocular pressure （IOP） in the treatment group at different time points showed no significant changes， however， IOP in the control group at different time points was significantly increased after treatment compared with before （P<0.05）. The incidence of elevated intraocular pressure was lower in the treatment group than in the control group after treatment （P<0.05）. Conclusion： The intravitreal injection of Compaq for the treatment of diabetic macular edema can significantly improve the visual acuity and reduce the macular edema. Its curative effect is similar to that of intravitreal injection of triamcinolone acetonide but with higher safety.

KEY WORDS conbercept ophthalmic injection； intravitreal injection； diabetic macular edema； vision； intraocular pressure

糖尿病性黃斑水腫（diabetic macular edema， DME）是糖尿病患者視力降低的主要原因。研究表明，患有糖尿病性黃斑水腫患者的玻璃體細(xì)胞間黏附分子-1（intercellular cell adhesion molecule-1， ICAM-1）和血管內(nèi)皮生長(zhǎng)因子（vascular endothelial growth factor， VEGF）表達(dá)水平升高[1]，因此臨床應(yīng)用玻璃體內(nèi)注射曲安奈德或康柏西普針進(jìn)行治療，然而兩者功效和安全性差異的報(bào)道尚較少見(jiàn)。在本研究中，我們比較了玻璃體內(nèi)注射康柏西普針或曲安奈德治療糖尿病性黃斑水腫的療效和安全性，報(bào)道如下。endprint